Targeting hIAPP fibrillation: A new paradigm to prevent β-cell death?

Biochim Biophys Acta Biomembr. 2022 Oct 1;1864(10):184002. doi: 10.1016/j.bbamem.2022.184002. Epub 2022 Jul 19.

Abstract

Loss of pancreatic β-cell mass is deleterious for type 2 diabetes patients since it reduces insulin production, critical for glucose homeostasis. The main research axis developed over the last few years was to generate new pancreatic β-cells or to transplant pancreatic islets as occurring for some specific type 1 diabetes patients. We evaluate here a new paradigm consisting in preservation of β-cells by prevention of human islet amyloid polypeptide (hIAPP) oligomers and fibrils formation leading to pancreatic β-cell death. We review the hIAPP physiology and the pathology that contributes to β-cell destruction, deciphering the various cellular steps that could be involved. Recent progress in understanding other amyloidosis such as Aβ, Tau, α-synuclein or prion, involved in neurodegenerative processes linked with inflammation, has opened new research lines of investigations to preserve neuronal cells. We evaluate and estimate their transposition to the pancreatic β-cells preservation. Among them is the control of reactive oxygen species (ROS) production occurring with inflammation and the possible implication of the mitochondrial translocator protein as a diagnostic and therapeutic target. The present review also focuses on other amyloid forming proteins from molecular to physiological and physiopathological points of view that could help to better decipher hIAPP-induced β-cell death mechanisms and to prevent hIAPP fibril formation.

Keywords: Amyloid proteins; Cross-fibrils; Pancreas; Type 2 diabetes; β-Cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid / chemistry
  • Cell Death
  • Diabetes Mellitus, Type 2* / metabolism
  • Humans
  • Inflammation
  • Islet Amyloid Polypeptide* / chemistry

Substances

  • Amyloid
  • Islet Amyloid Polypeptide